fda glp-1 warning news november 2025 What Patients Need to Know About the Policy Changes Semaglutide Safety Alerts, Recalls &

We dont make direct comparisons between compounded and name-brand products, and we always help patients understand their options before prescribing anything

TB-4 can also release Ac-SDKP, a smaller peptide studied for anti-scarring and anti-inflammatory effects (actin sequestration and Ac-SDKP release )

If you currently take Wegovy or are considering starting it, review your plans 2026 formulary or contact a BCBS representative to confirm any changes to your coverage

Nazir, S

It has a shorter half-life than semaglutide and tirzepatide, requiring daily injections rather than weekly

Using FDA-approved language to market it for general fat loss or body composition is a direct misrepresentation that appears in multiple recent warning letters